A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease–Associated Chronic Pain

Journal of Clinical Pharmacology

Volumn , Issue , 2016, Pages 852-861

  Rascol, Olivier ^a   Zesiewicz, Theresa ^b   Chaudhuri, K Ray ^c   Asgharnejad, Mahnaz ^d   Surmann, Erwin ^d   Dohin, Elisabeth ^d   Nilius, Sigrid ^d   Bauer, Lars ^d  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UCB PHARMA   (Belgium)

Author keywords

dopamine receptor agonist; pain; Parkinson's disease; pilot study; randomized controlled trial

Indexed keywords

PARACETAMOL; PLACEBO; ROTIGOTINE; TRAMADOL;

AGED; APPLICATION SITE REACTION; ARTICLE; BASAL CELL CARCINOMA; CHRONIC PAIN; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DYSKINESIA; EXPLORATORY RESEARCH; FALLING; FATIGUE; FEMALE; HEADACHE; HUMAN; INSOMNIA; LIKERT SCALE; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PARKINSON DISEASE; PILOT STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TRANSDERMAL PATCH; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 84974708334     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.678     Document Type: Article

References (47)

1. Sophie M, Ford B. Management of pain in Parkinson's disease. CNS Drugs. 2012;26(11):937–948.
2. Rana AQ, Kabir A, Jesudasan M, Siddiqui I, Khondker S. Pain in Parkinson's disease: analysis and literature review. Clin Neurol Neurosurg. 2013;115(11):2313–2317.
3. Broen MP, Braaksma MM, Patijn J, Weber WE. Prevalence of pain in Parkinson's disease: a systematic review using the modified QUADAS tool. Mov Disord. 2012;27(4):480–484.
4. Li W, Chen Y, Yin B, Zhang L. Pain in Parkinson's disease associated with COMT gene polymorphisms. Behav Neurol. 2014;2014:304203.
5. Mao C-J, Chen J-P, Zhang X-Y, et al. Parkinson's disease patients with pain suffer from more severe non-motor symptoms. Neurol Sci. 2015;36(2):263–268.
6. Wasner G, Deuschl G. Pains in Parkinson's disease—many syndromes under one umbrella. Nat Rev Neurol. 2012;8(5):284–294.
7. Defazio G, Gigante A, Mancino P, Tinazzi M. The epidemiology of pain in Parkinson's disease. J Neural Transm. 2013;120(4):583–586.
8. Ha AD, Jankovic J. Pain in Parkinson's disease. Mov Disord. 2012;27(4):485–491.
9. Truini A, Frontoni M, Cruccu G. Parkinson's disease related pain: a review of recent findings. J Neurol. 2013;260(1):330–334.
10. Politis M, Wu K, Molloy S, P GB, Chaudhuri KR, Piccini P. Parkinson's disease symptoms: the patient's perspective. Mov Disord. 2010;25(11):1646–1651.
11. Cury RG, Galhardoni R, Fonoff ET, et al. Sensory abnormalities and pain in Parkinson's disease and its modulation by treatment of motor symptoms. Eur J Pain. 2015.
12. Fil A, Cano-de-la-Cuerda R, Munoz-Hellin E, Vela L, Ramiro-Gonzalez M, Fernandez-de-Las-Penas C. Pain in Parkinson's disease: a review of the literature. Parkinsonism Relat Disord. 2013;19(3):285–294; discussion 285.
13. Ford B. Pain in Parkinson's disease. Clin Neurosci. 1998;5(2):63–72.
14. Ford B. Pain in Parkinson's disease. Mov Disord. 2010;25(Suppl 1):S98–S103.
15. Chaudhuri KR, Schapira AHV. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8(5):464–474.
16. Nègre-Pagès L, Regragui W, Bouhassira D, Grandjean H, Rascol O. Chronic pain in Parkinson's disease: the cross-sectional French DoPaMiP survey. Mov Disord. 2008;23(10):1361–1369.
17. Tinazzi M, Recchia S, Simonetto S, et al. Muscular pain in Parkinson's disease and nociceptive processing assessed with CO2laser-evoked potentials. Mov Disord. 2010;25(2):213–220.
18. Plan EL, Elshoff JP, Stockis A, Sargentini-Maier ML, Karlsson MO. Likert Pain Score modeling: A Markov integer model and an autoregressive continuous model. Clin Pharmacol Ther. 2012;91(5):820–828.
19. Ferreira-Valente MA, Pais-Ribeiro JL, Jensen MP. Validity of four pain intensity rating scales. Pain. 2011;152(10):2399–2404.
20. Hjermstad MJ, Fayers PM, Haugen DF, et al. Studies comparing numerical rating scales, verbal rating scales, and visual analogue scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manage. 2011;41(6):1073–1093.
21. Chaudhuri KR, Rizos A, Trenkwalder C, et al. King's Parkinson's disease pain scale, the first scale for pain in PD: an international validation. Mov Disord. 2015;30(12):1623–1631.
22. Scheller D, Ullmer C, Berkels R, Gwarek M, Lubbert H. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn-Schmiedebergs Arch Pharmacol. 2009;379(1):73–86.
23. Elshoff JP, Braun M, Andreas JO, Middle M, Cawello W. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther. 2012;34(4):966–978.
24. Elshoff J-P, Cawello W, Andreas J-O, Mathy F-X, Braun M. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome. Drugs. 2015;75(5):487–501.
25. Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007;6(6):513–520.
26. LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson's disease treated with rotigotine transdermal system: PREFER Study. Neurology. 2007;68(16):1262–1267.
27. Nicholas AP, Borgohain R, Chana P, et al. A randomized study of rotigotine dose response on “off” time in advanced Parkinsons disease. J Parkinsons Dis. 2014;4(3):361–373.
28. Jankovic J, Watts RL, Martin W, Boroojerdi B. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson's disease. Arch Neurol. 2007;64(5):676–682.
29. Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson's disease. Neurology. 2007;68(4):272–276.
30. Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord. 2007;22(16):2398–2404.
31. Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26(1):90–99.
32. Antonini A, Bauer L, Dohin E, et al. Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms—results of a double-blind, randomized, placebo-controlled trial. Eur J Neurol. 2015;22(10):1400–1407.
33. Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. J Neurol. 1998;245 (Suppl 1):S10–S14.
34. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–370.
35. MDS Task Force on Rating Scales for Parkinson's Disease. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord. 2003;18(7):738–750.
36. Kassubek J, Chaudhuri KR, Zesiewicz T, et al. Rotigotine transdermal system and evaluation of pain in patients with Parkinson's disease: a post hoc analysis of the RECOVER study. BMC Neurol. 2014;14:42.
37. Dworkin RH, Turk DC, McDermott MP, et al. Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations. Pain. 2009;146(3):238–244.
38. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94(2):149–158.
39. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006;5(3):235–245.
40. Schwarz J, Kassubek J, Oehlwein C, et al. A multicenter, non-interventional study with rotigotine to evaluate the perception of pain associated with idiopathic Parkinson's disease: the NEUPAD study. Presented at: Deutschen Gesellschaft für Neurologie 88th Jahreskongress; 23–26 September 2015; Düsseldorf, Germany.
41. Brefel-Courbon C, Payoux P, Thalamas C, et al. Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. Mov Disord. 2005;20(12):1557–1563.
42. Gerdelat-Mas A, Simonetta-Moreau M, Thalamas C, et al. Levodopa raises objective pain threshold in Parkinson's disease: a RIII reflex study. J Neurol Neurosurg Psychiatry. 2007;78(10):1140–1142.
43. Jung YJ, Kim HJ, Jeon BS, Park H, Lee WW, Paek SH. An 8-year follow-up on the effect of subthalamic nucleus deep brain stimulation on pain in Parkinson's disease. JAMA Neurol. 2015;72(5):504–510.
44. Madeo G, Schirinzi T, Natoli S, et al. Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson's disease patients with chronic pain. J Neurol. 2015;262(9):2164–2170.
45. Trenkwalder C, Chaudhuri KR, Martinez-Martin P, et al. Prolonged release oxycodone/naloxone for the treatment of severe Parkinson's disease-related pain: PANDA—a double-blind, randomized, placebo-controlled study. Lancet Neurol. 2015;14(12):1161–1170.
46. Schwarz KA, Buchel C. Cognition and the placebo effect—dissociating subjective perception and actual performance. PLoS One. 2015;10(7):e0130492.
47. Buchel C, Geuter S, Sprenger C, Eippert F. Placebo analgesia: a predictive coding perspective. Neuron. 2014;81(6):1223–1239.